IQVIA (NYSE:IQV) Issues FY 2026 Earnings Guidance

Key Points

• IQVIA issued FY 2026 guidance of EPS $12.650–$12.950 (consensus $12.460) and revenue guidance of $17.2B–$17.4B (consensus $17.2B).
• Analyst consensus remains a Buy with an average price target of $226.63, though several firms recently adjusted targets (e.g., JPMorgan and Citi cut, TD Cowen upgraded).
• IQVIA beat the latest quarter's estimates with $2.90 EPS vs. $2.83 expected and revenue of $4.15B vs. $4.10B, while the stock trades around $160.64 with a market cap of about $27.3B and a P/E of ~20.4.

IQVIA (NYSE:IQV - Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 12.650-12.950 for the period, compared to the consensus EPS estimate of 12.460. The company issued revenue guidance of $17.2 billion-$17.4 billion, compared to the consensus revenue estimate of $17.2 billion.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Morgan Stanley set a $240.00 target price on shares of IQVIA in a research report on Wednesday, February 11th. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $255.00 to $225.00 and set an "overweight" rating on the stock in a research report on Friday, February 6th. Citigroup reduced their target price on shares of IQVIA from $230.00 to $200.00 and set a "neutral" rating on the stock in a research report on Friday, February 6th. TD Cowen raised shares of IQVIA from a "hold" rating to a "buy" rating and boosted their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, Evercore restated an "outperform" rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $226.63.

IQVIA Stock Up 1.8%

IQV stock opened at $160.64 on Tuesday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA has a 1-year low of $134.65 and a 1-year high of $247.04. The firm has a fifty day moving average price of $169.36 and a two-hundred day moving average price of $201.53. The firm has a market cap of $27.26 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.57 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts predict that IQVIA will post 11.5 EPS for the current year.

Institutional Trading of IQVIA

Several institutional investors have recently added to or reduced their stakes in IQV. Brighton Jones LLC increased its stake in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after purchasing an additional 2,537 shares during the last quarter. Empowered Funds LLC grew its position in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company's stock worth $1,715,000 after acquiring an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of IQVIA during the second quarter worth about $514,000. First Trust Advisors LP grew its position in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company's stock worth $14,501,000 after acquiring an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC grew its position in shares of IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company's stock worth $3,582,000 after acquiring an additional 1,155 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.